Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416895 | 0.91 | MEN1 (0.53) | KDM4CMEN1KMT2AL3MBTL1RAB9A | |
| SCHEMBL5421663 | 0.90 | KDM4C (0.50) | KDM4CMEN1KMT2AL3MBTL1RAB9A | |
| SCHEMBL1008376 | 0.90 | MEN1 (0.53) | KDM4CMEN1KMT2AL3MBTL1RAB9A | |
| SCHEMBL14469419 | 0.89 | MEN1 (0.55) | KDM4CMEN1KMT2AL3MBTL1RAB9A | |
| SCHEMBL8500626 | 0.89 | MEN1 (0.55) | KDM4CMEN1KMT2AL3MBTL1RAB9A | |
| SCHEMBL10678875 | 0.88 | KDM4C (0.54) | KDM4CMEN1KMT2AL3MBTL1RAB9A | |
| SCHEMBL4077881 | 0.87 | KDM4C (0.50) | KDM4CMEN1KMT2AL3MBTL1RAB9A | |
| SCHEMBL5423863 | 0.87 | KDM4C (0.50) | KDM4CMEN1KMT2AL3MBTL1RAB9A | |
| SCHEMBL9574209 | 0.87 | MEN1 (0.53) | KDM4CMEN1KMT2AL3MBTL1RAB9A | |
| SCHEMBL1008487 | 0.87 | MEN1 (0.54) | KDM4CMEN1KMT2AL3MBTL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190701-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190701-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2011020193-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2011-02-24 | — | — | WO | disclosed |
| EP-0934940-A1 | CYTOKINE PRODUCTION INHIBITORS, TRIAZEPINE COMPOUNDS, AND INTERMEDIATES THEREOF | Japan Tobacco Inc. (JP) | 1999-08-11 | — | — | EP | disclosed |
| US-5807850-A | Therapeutic agent for osteoporosis and triazepine compound | JAPAN TOBACCO, INC. (JP) | 1998-09-15 | — | — | US | disclosed |
| EP-0792880-A1 | OSTEOPOROSIS REMEDY AND TRIAZEPINE COMPOUND | Japan Tobacco Inc. (JP) | 1997-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190701-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | KDM4C 2075/4885MEN1 3095/4885KMT2A 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.